Triglycerides: A risk factor for coronary heart disease

Atherosclerosis

Volumn 124, Issue SUPPL., 1996, Pages

  Davignon, Jean ^a   Cohn, Jeffrey S ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Atherosclerosis; Coronary heart disease (CHD); Hypertriglyceridaemia; Triglyceride rich proteins (TRL); Triglycerides (TG)

Indexed keywords

TRIACYLGLYCEROL;

ADULT; AGED; ATHEROGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029774756     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05858-3     Document Type: Conference Paper

References (42)

1. Austin MA. Plasma triglyceride and coronary heart disease. Arteriosclerosis 1991;11:2.
2. Austin MA, Goto C, Lenfant C, Tyroler HA. The hypertriglyceridemias: risk and management. 5. Epidemiology. Am J Cardiol 1991;68:22A.
3. Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300.
4. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Can J Cardiol 1988;4:5A.
5. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209.
6. Criqui MH, Heiss G, Cohn, R et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;17:1220.
7. Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetière P, Claude JR. Is the level of serum triglyceride a significant predictor of coronary death in 'normocholesterolemic' subjects? Am J Epidemiol 1986;124:624.
8. Hokanson JE, Austin MA. Triglyceride is a risk factor for coronary disease in men and women: a meta-analysis of population-based prospective studies. Circulation 1993;88(Suppl II):I-510.
9. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237.
10. Assmann G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Münster study. Am J Cardiol 1992;70:10H.
11. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37.
12. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arteriosclerosis Thromb 1993;13:702.
13. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993;69(Suppl 1):S34.
14. Davignon J. Fibrates: a review of important issues and recent findings. Can J Cardiol 1994;10:61B.
15. Rail SC Jr, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med 1992;231:653.
16. Fazio S, Hone Y, Simouet WS, Weisgraber KH, Taylor JM, Rail SC Jr. Altered lipoprotein metabolism in transgenic mice expressing low levels of a human receptorbinding defective apolipoprotein E variant. J Lipid Res 1994;35:408.
17. Van Vlijmen BJM, Van den Maagdenberg AMJM, Gijbels MJJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994;93:1403.
18. Hegele RA, Little JA, Vezina C et al. Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arteriosclerosis Thromb 1993;13:720.
19. Schaefer EJ, Gregg RE, Ghiselli G, et al. Familial apolipoprotein E deficiency. J Clin Invest 1986;78:1206.
20. Lussier-Cacan S, Bouthillier D, Davignon J. Apo E allele frequency in primary endogenous hypertriglyceridemia (Type IV) with and without hyperapobetalipoproteinemia. Arteriosclerosis 1985;5:639.
21. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Schwartz CJ and Born GVR. (eds.). New Horizons in Coronary Heart Disease. London: Current Science, 1993;5.1-5.21.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
23. Mattu RK, Needham EWA, Morgan R, et al. DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arteriosclerosis Thromb 1994;14:1090.
24. Hegele RA, Evans AJ, Tu L, Ip G, Brunt JH, Connelly PW. A gene-gender interaction affecting plasma lipoproteins in a genetic isolate. Arteriosclerosis Thromb 1994;14:671.
25. Minnich A, Kessling A, Roy M, et al. Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French-Canadian descent. J Lipid Res 1995;36:117.
26. Shimada M, Shimano H, Gotoda T, et al. Overexpression of human lipoprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J Biol Chem 1993;268:17 924.
27. 2-macroglobulin receptor/low-density lipoprotein receptor-related protein binds lipoprotein lipase and β-migrating very low-density lipoprotein associated with the lipase. J Biol Chem 1993;268:15 048.
28. Saxena U, Ferguson E, Bisgaier CL. Apolipoprotein E modulates low-density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. J Biol Chem 1993;268:14812.
29. Demant T, Bedford D, Packard CJ, Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 1991;88:1490.
30. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994;5:102.
31. Cohn JS. Postprandial lipid metabolism. Curr Opin Lipidol 1994;5:185.
32. Patsch JR, Miesenböck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arteriosclerosis Thromb 1992;12:1336.
33. Simpson HS, Williamson CM, Olivecrona T, et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990;85:193.
34. Simo IE, Yakichuk JA, Ooi TC. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 1993;100:55.
35. Syvänne M, Vuorinen-Markkola H, Hilden H, Taskinen MR. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arteriosclerosis Thromb 1993;13:286.
36. Karpe F, Steiner G, Uffelman K., Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83.
37. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42.
38. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762.
39. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969.
40. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and non-lipid factors. Circulation 1990;81:470.
41. Alaupovic P, Knight-Gibson C, Hodis HN, Mack WJ, Cashin-Hemphill L, Blankenhorn DH. Effect of apo B-containing lipoprotein particles on the progression of atherosclerotic lesions in the Monitored Atherosclerosis Regression Study (MARS). Atherosclerosis 1994;109:154.
42. Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti-apo B-100 and anti-apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993;223:53.